What is the address of DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE?

The registered office of DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE is located at Groene Jagerslaan 5, 1180 Ukkel.

Is DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE still active?

Yes. According to the CBE (2 October 2026) DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE is active, legal situation “Normale toestand”, started on 17 December 2008.

Is DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE registered on Peppol?

No, DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE is currently not registered on the Peppol network.

What is the enterprise number of DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE?

The enterprise number of DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE is BE0808487674.

When was DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE founded?

DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE was founded on 17 December 2008.

Who are the directors of DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE?

According to the 2025 annual accounts, the directors of DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE are: Patrick VAN BOGAERT, Rosine LEJEUNE.

Is DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 17 December 2008; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE make in 2025?

DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE posted a profit after taxes of € 10,941 in financial year 2025.

What is the revenue of DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE?

As a small company, DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 32,156.

DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE (Private Limited)

Dossier DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE, printed on 2 October 2026 from databakkes.be/en/0808487674/dr-rosine-lejeune-gynecologie-obstetrique. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2025

DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE from Ukkel, company number BE0808487674, closed financial year 2025 with a result of € 10,941 after tax. For that financial year DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE recorded a gross margin of € 32,156 and equity of € 99,528. Compared with financial year 2024, the result moved from € 3,839 to € 10,941. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 22, 2026.

What it is worth Healthy

€ 99,528

▼ 6% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 10,941

▲ 185% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 58,777

▼ 27% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 16,900 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Vehicles and equipment

€ 9,470

▼ 38% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 1,048

▼ 14% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 3,176

▲ 130% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 4,794

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 6,059 Gross margin 2022: € 6,059 First fiscal year in the series	€ 38,927 Gross margin 2023: € 38,927 ▲ € 32,867 vs 2022 (€ 6,059) Favourable step	€ 23,680 Gross margin 2024: € 23,680 ▼ 39% vs 2023 (€ 38,927) Unfavourable step	€ 32,156 Gross margin 2025: € 32,156 ▲ 36% vs 2024 (€ 23,680) Favourable step	▲ 36%
Profit after taxes	€ -1,928 Profit after taxes 2022: € -1,928 First fiscal year in the series	€ 19,672 Profit after taxes 2023: € 19,672 ▲ € 21,599 vs 2022 (€ -1,928) Favourable step	€ 3,839 Profit after taxes 2024: € 3,839 ▼ 80% vs 2023 (€ 19,672) Unfavourable step	€ 10,941 Profit after taxes 2025: € 10,941 ▲ 185% vs 2024 (€ 3,839) Favourable step	▲ 185%
Equity	€ 81,977 Equity 2022: € 81,977 First fiscal year in the series	€ 101,649 Equity 2023: € 101,649 ▲ 24% vs 2022 (€ 81,977) Favourable step	€ 105,487 Equity 2024: € 105,487 ▲ 4% vs 2023 (€ 101,649) Favourable step	€ 99,528 Equity 2025: € 99,528 ▼ 6% vs 2024 (€ 105,487) Unfavourable step	▼ 6%
Total debts	€ 51,879 Total debts 2022: € 51,879 First fiscal year in the series	€ 23,317 Total debts 2023: € 23,317 ▼ 55% vs 2022 (€ 51,879) Favourable step	€ 35,671 Total debts 2024: € 35,671 ▲ 53% vs 2023 (€ 23,317) Unfavourable step	€ 13,984 Total debts 2025: € 13,984 ▼ 61% vs 2024 (€ 35,671) Favourable step	▼ 61%
Cash	€ 79,564 Cash 2022: € 79,564 First fiscal year in the series	€ 49,478 Cash 2023: € 49,478 ▼ 38% vs 2022 (€ 79,564) Unfavourable step	€ 80,274 Cash 2024: € 80,274 ▲ 62% vs 2023 (€ 49,478) Favourable step	€ 58,777 Cash 2025: € 58,777 ▼ 27% vs 2024 (€ 80,274) Unfavourable step	▼ 27%
Retained profit	€ 63,377 Retained profit 2022: € 63,377 First fiscal year in the series	€ 83,049 Retained profit 2023: € 83,049 ▲ 31% vs 2022 (€ 63,377) Favourable step	€ 86,887 Retained profit 2024: € 86,887 ▲ 5% vs 2023 (€ 83,049) Favourable step	€ 80,928 Retained profit 2025: € 80,928 ▼ 7% vs 2024 (€ 86,887) Unfavourable step	▼ 7%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 16,900 Dividend 2025: € 16,900 Unchanged (€ 0) Unchanged
Bank debt	€ 1,430 Bank debt 2022: € 1,430 First fiscal year in the series	€ 7 Bank debt 2023: € 7 ▼ € 1,423 vs 2022 (€ 1,430) Favourable step	€ 1,213 Bank debt 2024: € 1,213 ▲ € 1,206 vs 2023 (€ 7) Unfavourable step	€ 1,048 Bank debt 2025: € 1,048 ▼ 14% vs 2024 (€ 1,213) Favourable step	▼ 14%
Balance sheet total	€ 133,856 Balance sheet total 2022: € 133,856 First fiscal year in the series	€ 124,966 Balance sheet total 2023: € 124,966 ▼ 7% vs 2022 (€ 133,856) Unchanged	€ 141,158 Balance sheet total 2024: € 141,158 ▲ 13% vs 2023 (€ 124,966) Unchanged	€ 113,512 Balance sheet total 2025: € 113,512 ▼ 20% vs 2024 (€ 141,158) Unchanged	▼ 20%

Key figures of DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE?

What happened at DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 22, 2026 New annual accounts for financial year 2025: profit of € 10,941 (▲ 185% vs 2024). Source: NBB ↗
Dec 17, 2008 Start of the company according to the CBE. KBO
Dec 4, 2008 New establishment in Ukkel. KBO

In short

From € 1,928 loss in 2022 to € 10,941 profit in 2025.

Paid € 18,085 in corporate taxes since 2022.

Best year ever: 2023, with € 19,672 profit.

Paid out € 16,900 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE? We notify you, reason included.

Follow DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Patrick VAN BOGAERT Rosine LEJEUNE

DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE

Behind DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE are Patrick VAN BOGAERT and Rosine LEJEUNE.

See the full network in the app

Directors

According to the 2025 annual accounts

Patrick VAN BOGAERT

Director

Rosine LEJEUNE

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Groene Jagerslaan 5

1180 Ukkel

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0808.487.674
VAT number: BE 0808.487.674
Registered office: Groene Jagerslaan 5, 1180 Ukkel
Names & denominations: DR ROSINE LEJEUNE,GYNECOLOGIE-OBSTETRIQUE
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 17 December 2008
Peppol: Not registered

View on CBE Public ↗ Annual accounts (NBB) ↗